Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/27/2025

Management of Seizure in a Patient on Bupropion and Rexulti

Immediate Actions

  • Discontinue bupropion immediately and permanently as it is contraindicated after a seizure has occurred, due to its significant lowering of the seizure threshold, with a dose-dependent risk of approximately 0.1% at doses up to 300 mg/day 1, 2
  • Stop bupropion at once, as it is absolutely contraindicated in patients with seizure disorders or a history of seizures, with the seizure risk being dose-dependent 1, 2, 3

Antiepileptic Therapy Decision

  • The American College of Physicians recommends selecting second-generation antidepressants based on adverse effect profiles, cost, and patient preferences, as efficacy does not differ significantly among agents, which can guide the choice of alternative antidepressants after bupropion discontinuation 4

Alternative Antidepressant Selection

  • Switch to an SSRI (sertraline, fluoxetine, escitalopram) or another second-generation antidepressant without significant seizure risk, as recommended by the American College of Physicians 4
  • Consider mirtazapine or vortioxetine as alternatives if the patient was benefiting from bupropion's activating properties or lower sexual side effect profile 4

Monitoring Plan

  • Monitor for seizure recurrence weekly for the first month after bupropion discontinuation, and assess for worsening depression, suicidal ideation, or behavioral changes with medication transition 4
  • Continue regular psychiatric follow-up to assess therapeutic response and adverse effects of the new antidepressant regimen, and modify treatment if no response after 6-8 weeks on adequate dosing of the new agent 4

Critical Pitfalls to Avoid

  • Never restart bupropion in this patient—a history of seizure is an absolute contraindication, as documented by the Journal of the National Comprehensive Cancer Network and other sources 1, 2, 3